PharmaEssentia (6446 TW) stock market data APIs
NT$503.9759
-9.27(-1.8%)
as of November 12, 2025
Try our APIs with
free plan!
PharmaEssentia Financial Data Overview
Price chart is built with
Anychart
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Prev. Close
503.9759
Open
494.7046
High
502.8466
Low
494.7046
52 wk Range
395.5448-715.5767
Market Cap
184 924 M
P/E Ratio
38.5505
Shares Outstanding
370 M
Revenue
13 815 M
EPS
3.99
Dividends (Yield)
0.002
Beta
-0.054
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with PharmaEssentia (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PharmaEssentia data using free add-ons & libraries
Get PharmaEssentia Fundamental Data
PharmaEssentia Fundamental data includes:
- Net Revenue: 13 815 M
- EBITDA: 4 031 M
- Earnings Per Share: 12
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: 4.31
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PharmaEssentia News
New
PharmaEssentia USA Announces Appointment of Dr. Barry Flannelly as Independent Director
Industry veteran brings deep commercial expertise to support the company’s continued growth and global expansion BURLINGTON, Mass., November 10, 2025--(BUSINESS WIRE)--PharmaEssentia USA Corporatio...
3 Global Stocks That May Be Undervalued In November 2025
As global markets experience fluctuations, with U.S. consumer sentiment nearing record lows and concerns about elevated valuations impacting growth-oriented stocks, investors are increasingly focused ...
High Growth Tech Stocks In Asia For November 2025
As the global economic landscape shifts, Asia's tech sector is capturing attention with its potential for high growth, particularly amidst easing U.S.-China trade tensions and Japan's record stock mar...
High Growth Tech Stocks In Asia To Watch This November 2025
As global markets navigate a period of mixed performance, with large-cap tech companies driving gains in the U.S. while smaller-cap indexes face declines, Asia's technology sector is drawing attention...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
